Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
2,284 results
  • Acquired Factor V Inhibitor with Hemorrhagic Symptoms after Prasugrel Hydrochloride Treatment. [Case Reports]
    Acta Haematol 2019; :1-3Sakatoku K, Takakuwa T, … Yamamura R
  • Acquired factor V inhibitor (AFVI) is a rare coagulopathy. It may be triggered by specific antigens such as antibiotics. We herein report the first case of AFVI after treatment with prasugrel hydrochloride (prasugrel) in an 80-year-old male who underwent percutaneous coronary intervention because of angina pectoris 6 years ago and was initiated on aspirin and ticlopidine hydrochloride. He was swi…
  • A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. [Journal Article]
    N Engl J Med 2019Claassens DMF, Vos GJA, … Ten Berg JM
  • CONCLUSIONS: In patients undergoing primary PCI, a CYP2C19 genotype-guided strategy for selection of oral P2Y12 inhibitor therapy was noninferior to standard treatment with ticagrelor or prasugrel at 12 months with respect to thrombotic events and resulted in a lower incidence of bleeding. (Funded by the Netherlands Organization for Health Research and Development; POPular Genetics number, NCT01761786; Netherlands Trial Register number, NL2872.).
  • Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. [Journal Article]
    N Engl J Med 2019Schüpke S, Neumann FJ, … ISAR-REACT 5 Trial Investigators
  • CONCLUSIONS: Among patients who presented with acute coronary syndromes with or without ST-segment elevation, the incidence of death, myocardial infarction, or stroke was significantly lower among those who received prasugrel than among those who received ticagrelor, and the incidence of major bleeding was not significantly different between the two groups. (Funded by the German Center for Cardiovascular Research and Deutsches Herzzentrum München; ISAR-REACT 5 number, NCT01944800.).
  • Pharmacodynamics During Transition Between Platelet P2Y12 Inhibiting Therapies. [Review]
    Interv Cardiol Clin 2019; 8(4):321-340Capranzano P, Francaviglia B, Angiolillo DJ
  • Several platelet P2Y12 inhibiting agents, both oral and intravenous, are available for clinical use. The oral P2Y12 inhibitors comprise clopidogrel, prasugrel, and ticagrelor. Cangrelor is the only intravenous P2Y12 inhibitor. Numerous pharmacodynamic studies have been performed to assess the impact of P2Y12 inhibitor switching on platelet reactivity profiles and to define the optimal strategy if…
New Search Next